Viewing nowOlmetec 20 mg Tablets (Olmesartan Medoxomil)
Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 200400472 · Approved 2004.10.29 · Insurance code 641602000
Treatment of essential hypertension
Essential hypertension uses medication to normalize blood pressure levels in order to reduce the risk of cardiovascular complications. This medication lowers blood pressure, thereby reducing the strain on the heart and blood vessels and helping to prevent serious complications such as stroke or myocardial infarction. Consistent use can enable blood pressure control and contribute to maintaining healthy blood vessels in the long term. Therefore, it is used for the treatment of essential hypertension.
<Adults> The recommended initial dose is 10 mg once daily, taken with or without food. If blood pressure is not adequately controlled at this dose, increase to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be used in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. <Elderly patients> No dose adjustment is necessary when administering this medicine to patients aged 65 years or older. No overall differences in the efficacy and safety of this medicine have been observed between elderly and younger patients; however, a more sensitive response in some elderly patients cannot be ruled out. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60 mL/min) is 20 mg once daily. <Patients with hepatic impairment> No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, which may be increased to a maximum of 20 mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with this medicine in these patients.
<Pediatrics> The safety and efficacy in pediatric patients have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be used in patients with allergies to this medication, during pregnancy or breastfeeding, those undergoing dialysis, patients with severe liver dysfunction, or patients with biliary obstruction. Patients with specific genetic issues, such as lactose intolerance, should not take this medication due to the lactose it contains. Caution is required when administering this medication to patients with low blood volume or low sodium levels, as blood pressure may drop too low initially; if hypotension occurs, immediate appropriate action must be taken. Patients with severe heart failure who rely on the renin-angiotensin-aldosterone system may experience a worsening of kidney function after taking this medication; therefore, periodic evaluations are necessary. It should be administered carefully to patients with poor kidney function or kidney transplant patients, and patients with renal artery stenosis also require caution. Because there is a risk of increased potassium levels in the blood during treatment, especially patients with heart or kidney diseases should have regular blood tests. Special caution is necessary when prescribing this medication to patients with aortic or mitral stenosis, or obstructive or hypertrophic myocardial disease. Patients with primary hyperaldosteronism may not respond well to this medication. Due to its blood pressure-lowering effects, dizziness may occur, so avoid driving or hazardous activities. Some ethnic groups may experience a slightly weaker effect on blood pressure reduction with this medication. Although generally safe to use, mild side effects such as dizziness, headache, palpitations, back pain, bronchitis, increased creatine phosphokinase, diarrhea, hematuria, hyperglycemia, hypertriglyceridemia, flu-like symptoms, pharyngitis, rhinitis, sinusitis, cough, abdominal pain, dyspepsia, gastroenteritis, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, hair loss, itching, epistaxis, and upper respiratory infections may occur. Rarely, symptoms such as angioedema or liver dysfunction, or allergic reactions may arise; consult a doctor immediately if any abnormal symptoms occur. If chronic diarrhea or severe abdominal pain occurs during treatment, stop taking this medication and consult your doctor. Caution is needed when used in combination with other antihypertensive drugs, potassium-sparing diuretics, or potassium supplements as blood potassium levels may dangerously increase. Avoid co-administration with lithium as it may lead to dangerously elevated lithium levels. Combining this medication with non-steroidal anti-inflammatory drugs may increase the risk of kidney function deterioration, so kidney function should be regularly monitored. Using this medication together with other drugs that have similar actions may increase the risks of hypotension, hyperkalemia, and kidney function deterioration, necessitating careful observation. Not taking this medication during pregnancy is the safest option for the health of the fetus, and breastfeeding mothers should consider stopping the medication or breastfeeding since this drug can be transmitted through breast milk. Safety and efficacy in pediatric populations have not been established. In elderly patients, as the concentration of this medication in the body may increase, dose adjustment and caution are necessary. In cases of overdose, hypotension and palpitations may appear; if symptoms are severe, seek medical attention immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is safe to store at room temperature between 1 to 25 degrees Celsius. By storing it this way, the medication's effectiveness can be maintained and its quality preserved.
White round film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowOlmesartan Medoxomil 20mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 40mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.